TITLE

Fusion protein denileukin diftitox clears psoriasis

AUTHOR(S)
Kuznar, Wayne
PUB. DATE
October 2001
SOURCE
Dermatology Times;Oct2001, Vol. 22 Issue 10, p18
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the effectiveness of dermatologic agents denileukin diftitox in clearing skin lesions in patients with psoriasis vulgaris in New York. Antipsoriatic activity of denileukin; Daily dosage administration; Decrease of lesional T-cells in the dermis.
ACCESSION #
5397133

 

Related Articles

  • Amevive Has Excellent Dose Response/Side-Effect Profile.  // Biotech Business;Jul99, Vol. 12 Issue 7, p1 

    Reports the result of the controlled trial of AMEVIVE, a recombinantly Engineered LFA-3/IgG1 Human Fusion Protein of Biogen Inc., in patients with moderate-to-severe chronic plaque psoriasis. Measurement of disease severity by Physician Global Assessment and the Psoriasis Activity and Severity...

  • Quality of life. Gagnon, Louise // Dermatology Times;Mar2009, Vol. 30 Issue 3, p49 

    The article discusses the use of combination therapy in treating psoriasis. It explains the use of methotrexate systemic retinoids or phototherapy as part of a combined therapy with biologic agents for treating psoriasis. According to Doctor Alan Menter, chairman of the psoriasis research unit...

  • Axys Initiates Phase II Clinical Trials of Tryptase Inhibitor.  // Biotech Business;Jul99, Vol. 12 Issue 7, p4 

    Reports that Axys Pharmaceuticals. Inc. has initiated a Phase II study of APC 2059 to evaluate the safety and effectiveness of a topically administered cream formulation for the treatment of mild to moderate psoriasis. Description of the Phase II human clinical study; Details on psoriasis;...

  • Can-Fite: therapeutic approach bolstered by positive results in psoriasis trial.  // PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p18 

    The article reports on the positive outcome of the psoriasis trial of Israel-based biopharmaceutical firm Can-Fite Biopharma Ltd. The 75-patient Phase II double-blind clinical study of the anti-TNF drug CF101 in patients with moderate to severe psoriasis resulted to efficacy upon oral...

  • Product News.  // Practice Nursing;Dec2012, Vol. 23 Issue 12, p629 

    The article offers news on recruitment and products such as, Pressure reducing pads by Crawford Healthcare Limited, Aquamol cream for psoriasis treatment and a recruitment advertisement for prescribing nurse practitioner at Chafford Hundred Medical Centre.

  • Prescribing emollients for dry skin conditions. Penzer, Rebecca // British Journal of Healthcare Management;Jul2014, Vol. 20 Issue 7, p315 

    Emollients are a key therapeutic product for the treatment of dry skin conditions. This article examines how emollients can be effectively prescribed to enhance patient outcomes and improve quality of life.

  • Managing psoriasis in children and young people. Van Onselen, Julie // Nurse Prescribing;Jul2013, Vol. 11 Issue 7, p330 

    Psoriasis is an inflammatory condition which manifests in the skin and joints. Psoriasis can affect children and young people; the late teens and early twenties are a peak time for psoriasis developing for the first time. Psoriasis can affect quality of life in children and young people. Nurses...

  • Dermatologic Look-Alikes. Scaling rash on the palms. STERN, ESTHER // Clinical Advisor;Oct2015, Vol. 18 Issue 10, p97 

    No abstract available.

  • Prescribing emollients for dry skin conditions. Penzer, Rebecca // Nurse Prescribing;Jun2013, Vol. 11 Issue 6, p276 

    Emollients are a key therapeutic product for the treatment of dry skin conditions. This article examines how emollients can be effectively prescribed to enhance patient outcomes and improve quality of life.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics